Background Hyperkalaemia is a common electrolyte abnormality caused by reduced renal
potassium excretion in patients with chronic kidney diseases (CKD). Potassium binders …

Background Patiromer and sodium zirconium cyclosilicate (SZC) are newer options for
hyperkalemia treatment. This systematic review and meta-analysis were conducted to …

Introduction Hyperkalemia is a common, potentially life-threatening condition in patients with
chronic kidney disease (CKD). We studied the association between hyperkalemia and …

Background The sodium-glucose cotransporter 2 inhibitor canagliflozin has been shown to
reduce the risk of cardiovascular and renal events in patients with Type 2 diabetes mellitus …

Recognition that neurohormonal activation plays a central role in the pathogenesis of heart
failure (HF) led to the development of angiotensin converting enzyme inhibitors (ACEIs) …

Hyperkalaemia is one of the most common electrolyte disorders in patients with
cardiovascular disease (CVD). The true burden of hyperkalaemia in the real-world setting …

Heart failure (HF) is a worrisome cardiac pandemic with a negative prognostic impact on the
overall survival of individuals. International guidelines recommend up-titration of …

Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with
advanced stages of chronic kidney disease (CKD), is a potentially life-threatening clinical …

Background: Although the management of hyperkalemia follows expert guidelines,
treatment approaches are based on traditionally accepted practice standards. New drugs …

Objective To evaluate the efficacy and safety of vonoprazan therapy as compared to
conventional proton pump inhibitors (PPIs) or no vonoprazan for non-erosive esophagitis …